Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021
May 12 2021 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late
clinical-stage biopharmaceutical company working to develop the
first FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, today announced it will host a Virtual
Clinical Day for analysts and accredited institutional investors
with live video webcast (details below) on Thursday, May 20, 2021
from 11:00 AM – 1:00 PM ET.
During the Virtual Clinical Day, Outlook
Therapeutics will provide an overview of its lead program, ONS-5010
/ LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic
formulation of bevacizumab for the treatment of wet age-related
macular degeneration (wet AMD), its ongoing Phase 3 study in wet
AMD, NORSE TWO, and its plans for a potential commercial
rollout.
Lawrence A. Kenyon, President, CEO and CFO of
Outlook Therapeutics will host the event and will be joined by
Outlook Therapeutics’ management team members, Terry Dagnon, Chief
Operating Officer, and Jeff Evanson, Chief Commercial Officer.
Key opinion leaders will also join the
management team to discuss Outlook Therapeutics’ current clinical
program and strategy, as well as the market need for a responsibly
priced, ophthalmic formulation of bevacizumab approved by the U.S.
Food and Drug Administration (FDA):
-
Mark Humayun, MD, PhD, Medical Advisor to Outlook
Therapeutics; Ophthalmologist, Engineer, Inventor; National Medal
of Technology and Innovation awarded by President Barack Obama,
2016; Top 1% Ophthalmologists (U.S. News & World Report);
Member, U.S. National Academics of Medicine and Engineering; Pyron
Award, American Society of Retina Specialists; Past President,
American Society of Retina Specialists; Co-inventor of Argus II,
which offers functional sight to patients with complete retinal
blindness
-
Firas M. Rahhal, MD, Senior Partner,
Retina-Vitreous Associates Medical Group in Los Angeles and
Associate Clinical Professor of Ophthalmology at the UCLA Geffen
School of Medicine
Webcast Details
Interested participants and investors may dial
into the event using (877) 407-9708 (domestic) or (201) 689-8259
(international), or can access the live video webcast and
accompanying slide presentation on the Events page of the Investors
section of the Outlook Therapeutics website,
outlooktherapeutics.com. The webcast replay will be archived for 90
days following the event.
About ONS-5010 / LYTENAVA™
(bevacizumab-vikg)
ONS-5010 is an investigational ophthalmic
formulation of bevacizumab under development to be administered as
an intravitreal injection for the treatment of wet AMD and other
retinal diseases. Because no currently approved ophthalmic
formulations of bevacizumab are available, clinicians wishing to
treat retinal patients with bevacizumab have had to use unapproved
repackaged IV bevacizumab provided by compounding pharmacists,
products that have known risks of contamination and inconsistent
potency and availability. If approved, ONS-5010 will reduce the
need for use of unapproved repackaged IV bevacizumab from
compounding pharmacists for retinal disease.
ONS-5010 is a full-length, humanized anti-VEGF
(Vascular Endothelial Growth Factor) recombinant monoclonal
antibody (mAb) that inhibits VEGF and associated angiogenic
activity. VEGF is a protein that promotes the growth of new
abnormal blood vessels. With wet AMD, abnormally high levels of
VEGF are secreted in the eye and lead to loss of vision. Anti-VEGF
injection therapy blocks this growth. Since the advent of anti-VEGF
therapy, it has become the standard-of-care treatment option within
the retina community globally.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage
biopharmaceutical company working to develop ONS-5010/LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
diabetic macular edema and branch retinal vein occlusion. If
ONS-5010 is approved, Outlook Therapeutics expects to commercialize
it as the first and only FDA-approved ophthalmic formulation of
bevacizumab for use in treating a range of retinal diseases in the
United States, United Kingdom, Europe, Japan, China and other
markets. Outlook Therapeutics expects to file ONS-5010 with the
U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway,
initially for wet AMD. For more information, please visit
www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries:Harriet UllmanAssistant Vice
PresidentLaVoieHealthScienceT:
617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:
Jenene ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2023 to Apr 2024